Note 7 - Inventory |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2021 | |||||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||
| Inventory Disclosure [Text Block] |
The components of net inventory as of December 31, 2021 and 2020 are presented in the following table.
During 2021 and 2020, we utilized $28,000 and $11,000, respectively, of materials inventory for process development purposes. Also during 2021 and 2020, we allocated $0 and $39,000, respectively, of finished goods inventory for use in clinical trials. These transactions were recorded in research and development expense in the consolidated statement of operations.
|
||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|